Galectin Therapeutics And Providence Portland Medical Center Receive OK From FDA To Proceed With Phase 1B Clinical Trial In Metastatic Melanoma
2/4/2014 9:28:39 AM
NORCROSS, Ga., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed that a Phase 1B clinical trial of the galectin inhibitor GR-MD-02 in combination with Yervoy® (ipilimumab) in patients with metastatic melanoma may proceed. Providence Portland Medical Center, a leader in immunotherapy research and translational clinical trials in melanoma and other cancers, filed the IND in late December 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by